Test of the Month

You have full text access to this OnlineOpen article

Laboratory testing for fibrinogen abnormalities†

  1. Madeleine Verhovsek1,2,
  2. Karen A. Moffat2,3,
  3. Catherine P.M. Hayward1,2,3,*

Article first published online: 23 SEP 2008

DOI: 10.1002/ajh.21293

Issue

American Journal of Hematology

American Journal of Hematology

Volume 83, Issue 12, pages 928–931, December 2008

Additional Information

How to Cite

Verhovsek, M., Moffat, K. A. and Hayward, C. P.M. (2008), Laboratory testing for fibrinogen abnormalities. Am. J. Hematol., 83: 928–931. doi: 10.1002/ajh.21293

Author Information

  1. 1

    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada

  2. 2

    Department of Medicine, McMaster University, Hamilton, Ontario, Canada

  3. 3

    Hamilton Regional Laboratory Medicine Program, Hamilton, Ontario, Canada

*Room 2N30, McMaster University Medical Center, 1200 Main St. West, Hamilton, Ontario, Canada L8N 3Z5

  1. †

    Conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 20 NOV 2008
  2. Article first published online: 23 SEP 2008
  3. Accepted manuscript online: 23 SEP 2008 12:00AM EST
  4. Manuscript Accepted: 13 SEP 2008
  5. Manuscript Revised: 11 SEP 2008
  6. Manuscript Received: 9 JUL 2008

Funded by

  • Career Investigator Award from the Heart and Stroke Foundation of Ontario
  • Canada Research Chair in Molecular Hemostasis

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (65K)

References

  • 1
    Colman RW,Marder VJ,Clowes AW, et al. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
  • 2
    Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894–1904.
    Direct Link:
  • 3
    Cerneca F,Ricci G,Simeone R, et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997; 73: 31–36.
  • 4
    Gjonnaess H,Fagerhol MK,Stormorken H. Studies on coagulation and fibrinolysis in blood from puerperal women with and without oestrogen treatment. Br J Obstet Gynaecol 1975; 82: 151–157.
  • 5
    Deutsche E. Blood coagulation changes in liver disease. Prog Liver Dis 1965; 2: 69–83.
  • 6
    Famodu AA,Adedeji MO,Reid HL. Serial plasma fibrinogen changes accompanying sickle cell pain crisis. Clin Lab Haematol 1990; 12: 43–47.
    Direct Link:
  • 7
    Irish A. Cardiovascular disease, fibrinogen and the acute phase response: Associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 1998; 137: 133–139.
  • 8
    Rice EW. Plasma fibrinogen, cholinesterase activity, and anemia: Utility of fibrinogen in multiphasic screening and in assessing the activity of diseases. Clin Chem 1977; 23: 741–742.
  • 9
    Haire WD. Pharmacology of fibrinolysis. Chest 1992; 101: 91S–97S.
  • 10
    Lechner K,Niessner H,Thaler E. Coagulation abnormalities in liver disease. Semin Thromb Hemost 1977; 4: 40–56.
  • 11
    Mannucci PM,Duga S,Peyvandi F. Recessively inherited coagulation disorders. Blood 2004; 104: 1243–1252.
  • 12
    Peyvandi F,Kaufman RJ,Seligsohn U, et al. Rare bleeding disorders. Haemophilia 2006; 12 ( Suppl 3): 137–142.
    Direct Link:
  • 13
    Acharya SS,Coughlin A,Dimichele DM. Rare Bleeding Disorder Registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2: 248–256.
    Direct Link:
  • 14
    Francis JL,Armstrong DJ. Sialic acid and enzymatic desialation of cord blood fibrinogen. Haemostasis 1982; 11: 223–228.
  • 15
    Martinez J,Keane PM,Gilman PB,Palascak JE. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease. Ann NY Acad Sci 1983; 408: 388–396.
    Direct Link:
  • 16
    Van Cott EM,Smith EY,Galanakis DK. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time. Am J Clin Pathol 2002; 118: 263–268.
  • 17
    Quick AJ,Hussey CV,Geppert M. Prothrombin: Analytical and clinical aspects. Comparison of the one- and two-stage methods. Am J Med Sci 1963; 246: 517–526.
  • 18
    Latallo ZS,Teisseyre E. Evaluation of Reptilase R and thrombin clotting time in the presence of fibrinogen degradation products and heparin. Scand J Haematol Suppl 1971; 13: 261–266.
  • 19
    Langdell RD,Wagner RH,Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests; a presumptive test for hemophilia and a simple one-stage antihemophilic factor assy procedure. J Lab Clin Med 1953; 41: 637–647.
  • 20
    Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17: 237–246.
  • 21
    Chitolie A,Mackie IJ,Grant D, et al. Inaccuracy of the ‘derived’ fibrinogen measurement. Blood Coagul Fibrinolysis 1994; 5: 955–957.
  • 22
    Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45–52.
  • 23
    Haverkate F,Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151–161.
  • 24
    Lak M,Keihani M,Elahi F, et al. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107: 204–206.
    Direct Link:
  • 25
    Mosesson MW. Dysfibrinogenemia and thrombosis. Semin Thromb Hemost 1999; 25: 3111–319.
  • 26
    Marchi R,Mirshahi SS,Soria C, et al. Thrombotic dysfibrinogenemia: Fibrinogen “Caracas V” relation between very tight fibrin network and defective clot degradability. Thromb Res 2000; 99: 187–193.
  • 27
    Siebenlist KR,Mosesson MW,Meh DA, et al. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11: 293–304.
Get PDF (65K)